Breithardt G, Haerten K, Seipel L
Z Kardiol. 1976 Aug;65(8):713-23.
Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias. The effect of disopyramide was compared to a pretreatment with one or several antiarrhythmic drugs (quinidine, beta-blocking agents, verapamil, ajmalin-bitartrat, aprindine, propafenone, diphenylhydantoin) which had been discontinued either due to ineffectiveness or the occurrence of intolerable side effects. Therapeutical effectiveness was controlled by on-line arrhythmia computers in the CCU or Holter monitoring. 15 patients were treated longer than 4 weeks up to 16 months (mean 35+/-22,6 weeks). The following results were achieved: 1 atrial fibrillation, abolition or significant reduction of the rate of recurrence in 10 out of 23 patients; slight reduction or no effect in 13 patients; 2. ventricular ectopic beats: abolition or significant reduction in 6 out of 16 patients, slight reduction or no effect in the remaining 10 patients. Patients who were treated successfully received the same dosis as those without therapeutical success. In cases with atrial fibrillation, the success was dependent on the duration of this arrhythmia prior to treatment. In comparison to the pretreatment with one or several of the above-mentioned anti-arrhythmic drugs, disopyramide was as effective as the drug given before. The analysis of the Ecg revealed a slight but insignificant prolongation of the time intervals. In 22 patients reversible dosage-dependent side effects were observed which are due to the vagolytic action of the drug: dry mouth, blurred vision, urinary hesitancy, nausea, headache. These side effects occurred at daily dosages between 400 to 800 mg increasing markedly in patients on 800 mg a day. The drug had to be discontinued in 4 cases because of side effects. During long-term treatment no severe side effects were observed. Thus, disopyramide may serve as an alternative to quinidine, especially if the latter has to be stopped because of side effects.
对39例患有不同类型慢性心律失常的患者进行了丙吡胺(B 712)的测试:23例心房颤动患者,16例室性早搏患者,2例室上性心动过速患者。将丙吡胺的效果与使用一种或几种抗心律失常药物(奎尼丁、β受体阻滞剂、维拉帕米、阿马林-酒石酸盐、茚丙胺、普罗帕酮、苯妥英钠)进行预处理的效果进行比较,这些药物因无效或出现无法耐受的副作用而停用。治疗效果通过CCU中的在线心律失常计算机或动态心电图监测进行控制。15例患者治疗时间超过4周,最长达16个月(平均35±22.6周)。取得了以下结果:1. 心房颤动:23例患者中有10例发作消除或复发率显著降低;13例患者略有降低或无效果;2. 室性早搏:16例患者中有6例消除或显著降低,其余10例患者略有降低或无效果。治疗成功的患者与治疗未成功的患者服用相同剂量。在心房颤动病例中,成功与否取决于治疗前该心律失常的持续时间。与使用上述一种或几种抗心律失常药物进行预处理相比,丙吡胺的效果与之前使用的药物相同。心电图分析显示时间间期略有延长,但无统计学意义。在22例患者中观察到可逆的剂量依赖性副作用,这是由于该药物的抗迷走神经作用所致:口干、视力模糊、排尿犹豫、恶心、头痛。这些副作用发生在每日剂量400至800毫克之间,每天服用800毫克的患者中副作用明显增加。4例患者因副作用不得不停药。长期治疗期间未观察到严重副作用。因此,丙吡胺可作为奎尼丁的替代药物,特别是在因副作用必须停用奎尼丁的情况下。